Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1997-04-04
2000-02-08
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
514603, 514651, 514652, 514654, 514655, 564349, 564350, 564351, A61K 31135
Patent
active
060228946
ABSTRACT:
The present invention features calcilytic compounds. "Calcilytic compounds" refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.
REFERENCES:
patent: 4067904 (1978-01-01), Corner et al.
patent: 4235919 (1980-11-01), Berthold
patent: 4289883 (1981-09-01), Tominaga et al.
patent: 4302588 (1981-11-01), Tominaga et al.
patent: 4332787 (1982-06-01), Homcy et al.
patent: 4376125 (1983-03-01), Brooker et al.
patent: 5763569 (1998-06-01), Brown et al.
patent: 5786356 (1998-07-01), Bell et al.
Abrahamsson et al., "The .beta..sub.1 - and .beta..sub.2 -Adrenoceptor Affinity of Atenolol and Metoprolol: A Receptor-Binding Study Performed With Different Radioligands in Tissues from the Rat, The Guinea Pig, and Man," Biochemical Pharmacology 37(2):203-208 (1988).
Aggerbeck et al., "Characterization of the .alpha.-Adrenoreceptor of Rat Liver Plasma Membrane. Structure Affinity relationship and role of the aralkyl substituent on the amino group," Recent Advances in the Pharmacology of Adrenoceptors: Proceedings of a Satellite Symposium of the 7th International Congress of Pharmacology held at Owens Park, Manchester pp. 345-346 (1978).
Aggerbeck et al., "N-Aralkyl Substitution Increases the Affinity of Adrenergic Drugs for the .alpha.-Adrenoceptor in Rat Liver," Br. J. Pharmacol. 65(1):155-159 (1979).
Auerbach et al., "Neonatal Rat Pinealocytes: Typical and Atypical Characteristics of [.sup.125 I]Iodohydroxybenzylpindolol Binding and Adenosine 3', 5'-Monophosphate Accumulation," Endocrinology 108(2):559-567 (1981).
Aurbach et al., ".beta.-Adrenergic Receptor: Sterospecific Interaction of Iodinated .beta.-Blocking Agent with High Affinity Site," Science 186:1223-1224 (1974).
Bakardjieva et al., "Modulation of the .beta.-Receptor Adenylate Cyclase Interactions in Cultured Chang Liver Cells by Phospholipid Enrichment," Biochemistry 18(14):3016-3023 (1979).
Baker et al., "The Synthesis of N-Alkylated p-Chlorophentermine Derivatives and Their Effects on Release of 5-Hydroxytryptamine From Rat Striatum in Vitro," Canadian Journal of Pharmaceutical Sciences 15(4):71-74 (1980).
Bearer et al., "Iodohydroxybenzylpindolol: Preparation, Purification, Localization of Its Iodine to the Indole Ring, and Characterization as a Partial Agonist," Molecular Pharmacology 17(3):328-338 (1980).
Bilezikian et al., "Structure-Binding Activity Analysis of Beta-Adrenergic Amines--II. Binding to the Beta Receptor and Inhibition of Adenylate Cyclase," Biochemical Pharmacology 27(10):1455-1461 (1978).
Braun et al., "The Interaction of Mn.sup.2+ with Turkey Erythrocyte Adenylate Cyclase," Biochimica et Biophysica Acta 705(1):55-62 (1982).
Brown et al., ".beta.-Adrenergic Receptor Interactions: Characterization of Iodohydroxylbenzylpindolol As A Specific Ligand," J. Biol. Chem. 25(5):1232-1238 (1976).
Brown et al., ".beta.-Adrenergic Receptor Interactions: Direct Comparison of Receptor Interaction and Biological Activity," J. Biol. Chem. 251(5):1239-1246 (1976).
Brown et al., "Cloning and characterization of an extracellular Ca.sup.2+ -sensing receptor from bovine parathyroid," Nature 366:575-580 (1993).
Brown et al., "Direct Determination of Ligand Interactions with Beta-Adrenergic Receptors on Intact Turkey Erythrocytes: Correlation of Binding with Biological Activity," Endocrinology 99(5):1370-1376 (1976).
Brown et al., "Neomycin Mimics the Effects of High Extracellular Calcium Concentrations on Parathyroid Function in Dispersed Bovine Parathyroid Cells," Endocrinology 128:3047-3054 (1991).
Burgisser et al., "Anomalous Equilibrium Binding Properties of High-Affinity Racemic Radioligands," Molecular Pharmacology 19(2):205-216 (1981).
Bylund and Snyder, "Beta Adrenergic Receptor Binding in Membrane Preparations from Mammalian Brain," Molecular Pharmacology 12(4):568-580 (1976).
Bylund et al., "Beta Adrenergic Receptor Labeling in Intact Animals with .sup.125 I-Hydroxybenzylpindolol," The Journal of Pharmacology and Experimental Therapeutics 201(3):644-653 (1977).
Castedo et al., ".beta.-Adrenergic Blockers: Synthesis of R-1-[(1,1-dimethyl-2-phenylethyl) amino]-3-(3,4-dichlorophenoxy)-2-propanol," Anales De Quimica, Ser. C, 80(3):291-294 (1984).
Chen and Brown, "The Diltiazem Analog TA-3090 Mimics the Actions of High Extracellular Ca.sup.2+ on Parathyroid Function in Dispersed Bovine Parathyroid Cells," Journal of Bone and Mineral Research 5:581-587 (1990).
Condon et al., "Nondepressant .beta.-Adrenergic Blocking Agents. 1. Substituted 3-Amino-1-(5,6,7,8-tetrahydro-1-naphthoxy)-2-propanols," J. Med. Chem. 21(9):913-922 (1978).
Crowther et al., ".beta.-Adrenergic Blocking Agents. 12. Heterocyclic Compounds Related to Propranolol," J. Med. Chem. 15(3):260-266 (1972).
Dax and Partilla, "Adrenergic Ligand Liposolubility in Membranes: Direct Assessment in a Beta-Adrenergic Binding System," Molecular Pharmacology 22(1):5-7 (1982).
Dax et al., "Quantitation of Beta Adrenergic Receptors in Rat Liver: Confounding Effect of Displaceable But Nonsterospecific Antagonist Binding," Journal of Receptor Research 2(3):267-283 (1981).
Dempster et al., "Anabolic Actions of Parathyroid Hormone on Bone," Endocrine Reviews 14(6):690-709 (1993).
Eckelman et al., "In vivo Competition Studies with Analgoues of 3-Quinuclidinyl Benzilate," Journal of Pharmaceutical Sciences 73(4):529-534 (1984).
Eckelman et al., "Radiochemistry and Radiopharmaceuticals: In Vivo Receptor Binding of Iodinated Beta-Adrenoceptor Blockers," J. Nucl. Med. 21(5):436-442 (1980).
Espinosa and Ibanez-Paniello, ".beta. Blocking Adrenergics: Synthesis and Resolution of 1-[(1,1-dimethyl-2-phenylethyl) amino]-3-aryloxy-2-propanols," Anales De Quimica, Ser. C, 77(1):22-27 (1981).
Espinosa and Ibanez-Paniello, "Adrenergic .beta.-Blockers: Synthesis of 1-[(1,1-dimethyl-2-phenylethyl) amino]-3-aryloxy-2-propanols," Anales De Quimica, Ser. C, 77(3):361-365 (1981).
Esplugues et al., "Experimental Evaluation of Antianginal Drugs," Revista Espanola de Fisiologia 34(1):15-20 (1978).
Ezrailson et al., "[.sup.125 I]Iodopindolol: A New .beta. Adrenergic Receptor Probe," J. Cyclic Nucleotide Research 7(1):13-26 (1981).
Fleming and Ross, "Reconstitution of Beta-Adenergic Receptors Into Phospholipid Vesicles: Restoration of [.sup.125 I]Iodohydroxybenzylpindolol Binding to Digitonin-Solubilized Receptors," J. Cyclic Nucleotide Research 6(6):407-419 (1980).
Gao et al., "Radioiodination and Pharmacokinetics of Bivalent Analog of Practolol as Myocardial Imaging Agent," Nuclear Science and Techniques 6(4):238-240 (1995).
Garrett et al., "Calcitonin-Secreting Cells of the Thyroid Express an Extracellular Calcium Receptor Gene," Endocrinology 136(11):5202-5211 (1995).
Goretzki et al., "Absence of high-affinity binding sites for beta-adrenergic blockers and lack of adenyl cyclase stimulation to beta-adrenergic stimulators in most normal and adenomatous human thyroid tissues," Surgery 96(6):1001-1008 (1984).
Gregory et al., "Ch. 8--The Beta-Adenergic Receptor and Adenyl Cyclase of Rabbit Ciliary Processes," in New Directions in Ophthalmic Research, edited by Sears, Yale University Press, New Haven and London, pp. 127-145 (1981).
Guellaen et al., "Characterization and Solubilization of the .alpha.-Adrenoreceptor of Rat Liver Plasma Membranes Labeled with [.sup.3 H]Phenoxybenzamine," J. Biol. Chem. 254(21):10761-10768 (1979).
Hanel et al., "New systemically active antimycotics from the beta-blocker category," Mycoses 38(7/8):251-264 (1995).
Harada et al., "Studies on Uricosuric Diuretics. I. 6,7-Dichloro-5-sulfamoyl-2,3-dihydrobenzofuran-2-carboxylic Acids," Chem. Pharm. Bull. 35(8):3195-3214 (1987).
Harden et al., "Binding of Iodinated Beta Adrenergic Antagonists to Proteins Derived from Rat Heart," Molecular Pharmacology 12:1-15 (1976).
Heidenreich et al., "Characterization of Radiolabeled Agonist Binding to .beta.-Adrenergic Receptors in Mammalian Tissues," J. Cyclic Nucleotide Research
Barmore Robert M.
Callahan James F.
Del Mar Eric G.
Keenan Richard M.
Kotecha Nikesh R.
NPS Pharmaceuticals Inc.
Raymond Richard L.
SmithKline Beecham Corp.
SmithKline Beecham plc
LandOfFree
Method of using calcilytic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of using calcilytic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of using calcilytic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1681759